Nov 28, 2018
MabVax Therapeutics Holdings, Inc. Announces $1.0 Million Equity Purchase Agreement
Sep 21, 2018
Delaware Court of Chancery Grants Petition Filed by MabVax Therapeutics
Aug 08, 2018
MabVax Therapeutics Announces Auditor Resignation
Jul 09, 2018
MabVax Therapeutics and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers
Jul 06, 2018
MabVax Therapeutics' HuMab-5B1 ImmunoPET Imaging Agent MVT-2163 Subject of National Institutes of Health R01 Research Grant Awarded to Memorial Sloan Kettering Cancer Center
Jul 05, 2018
MabVax Therapeutics Receives Nasdaq Delist Determination
Jun 27, 2018
MabVax Therapeutics Receives Superseding Letter Related to the Late Filing of Form 10-Q
May 03, 2018
MabVax Therapeutics Holdings, Inc. Announces Private Placement Offering
Apr 30, 2018
MabVax Therapeutics to Present an Interactive Live Webcast at VirtualInvestorConferences.com
Apr 13, 2018
MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements
Apr 02, 2018
MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones
Feb 15, 2018
MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement
Feb 12, 2018
MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer
Feb 07, 2018
MabVax to Present at BIO CEO & Investor Conference
Jan 30, 2018
MabVax Receives Notice of SEC Investigation and Examination of Certain Registration Statements
Dec 20, 2017
MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy
Dec 13, 2017
MabVax Therapeutics Announces Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers
Nov 16, 2017
MabVax Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements
Nov 13, 2017
MabVax Therapeutics to Present Positive Development Study Results Enabling Manufacturing of Two Radionuclide Products for Phase 1 Clinical Trials at the 2017 AAPS Annual Meeting
Oct 31, 2017
MabVax Therapeutics Provides Update on the MVT-5873 Phase 1 Clinical Program and Expansion of Preclinical Development Pipeline at the AACR-NCI-EORTC International Conference